PT - JOURNAL ARTICLE AU - Helwick, Caroline ED - Nissen, Steven TI - Torcetrapib Fails to Meet Expectations DP - 2007 Jun 01 TA - MD Conference Express PG - 17--20 VI - 7 IP - 1 4099 - http://mdc.sagepub.com/content/7/1/17.short 4100 - http://mdc.sagepub.com/content/7/1/17.full AB - Increased levels of high-density lipoprotein cholesterol decrease the risk of cardiovascular disease. Torcetrapib, a cholesteryl-ester-transfer protein inhibitor, has a potent effect on increasing HDL-C levels that was hoped would translate into the halting or reversal of atherosclerosis. The results from three clinical trials of torcetrapib are discussed in this article.